Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 11Recurrence 5Leukemia 5Myelodysplastic Syndromes 2Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia, Erythroblastic, Acute 1Aortic aneurysm, familial thoracic 4 1

Interventions

fludarabine phosphate 36Whole-Body Irradiation 30Cyclophosphamide 30Mycophenolic Acid 28Azacitidine 27Tacrolimus 25Peripheral Blood Stem Cell Transplantation 24Busulfan 22Methotrexate 15Cyclosporine 15Antilymphocyte Serum 14Decitabine 11Cytarabine 11Melphalan 10fludarabine 9Radiotherapy 8Filgrastim 8Granulocyte Colony-Stimulating Factor 7Etoposide 7Cord Blood Stem Cell Transplantation 7thymoglobulin 6Sirolimus 6Rituximab 6Cyclosporins 6Clofarabine 6venetoclax 5merphos 5Sorafenib 4Lenalidomide 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelomonocytic, Chronic × quizartinib × Clear all
NCT01892371 2025-04-06

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Completed
73 enrolled 12 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡